179 related articles for article (PubMed ID: 33154299)
41. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
[TBL] [Abstract][Full Text] [Related]
42. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
[TBL] [Abstract][Full Text] [Related]
43. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
44. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
45. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
[TBL] [Abstract][Full Text] [Related]
46. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
47. Current role of primary surgical treatment in patients with head and neck squamous cell carcinoma.
Bozec A; Culié D; Poissonnet G; Dassonville O
Curr Opin Oncol; 2019 May; 31(3):138-145. PubMed ID: 30865132
[TBL] [Abstract][Full Text] [Related]
48. Cell-free mitochondrial DNA copy number variation in head and neck squamous cell carcinoma: A study of non-invasive biomarker from Northeast India.
Kumar M; Srivastava S; Singh SA; Das AK; Das GC; Dhar B; Ghosh SK; Mondal R
Tumour Biol; 2017 Oct; 39(10):1010428317736643. PubMed ID: 29072129
[TBL] [Abstract][Full Text] [Related]
49. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
50. Quantification of plasma cell-free DNA levels in dogs with various tumors.
Tagawa M; Shimbo G; Inokuma H; Miyahara K
J Vet Diagn Invest; 2019 Nov; 31(6):836-843. PubMed ID: 31585514
[TBL] [Abstract][Full Text] [Related]
51. Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature.
van Ginkel JH; Slieker FJB; de Bree R; van Es RJJ; Van Cann EM; Willems SM
Oral Oncol; 2017 Dec; 75():8-15. PubMed ID: 29224828
[TBL] [Abstract][Full Text] [Related]
52. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
53. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
[No Abstract] [Full Text] [Related]
54. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.
de Vos L; Gevensleben H; Schröck A; Franzen A; Kristiansen G; Bootz F; Dietrich D
Clin Epigenetics; 2017; 9():125. PubMed ID: 29213339
[TBL] [Abstract][Full Text] [Related]
55. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
56. Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Rambeau A; Bastit V; Thureau S; Thariat J; Moldovan C; Roge M; Babin E; Gery B; Di Fiore F; Florescu C; Clatot F
Oral Oncol; 2019 Jun; 93():46-51. PubMed ID: 31109695
[TBL] [Abstract][Full Text] [Related]
57. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
Yu Z; Qin S; Wang H
J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
[TBL] [Abstract][Full Text] [Related]
58. Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience.
Nagpal P; Pruthi DS; Pandey M; Yadav A; Singh H
Oral Oncol; 2021 Oct; 121():105483. PubMed ID: 34403887
[TBL] [Abstract][Full Text] [Related]
59. Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.
Kumari S; Tewari S; Husain N; Agarwal A; Pandey A; Singhal A; Lohani M
Pathol Oncol Res; 2017 Jan; 23(1):91-97. PubMed ID: 27475647
[TBL] [Abstract][Full Text] [Related]
60. Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F; Alix-Panabières C; Lafont T; Allal BC; Garrel R; Digue L; Guigay J; Cupissol D; Delord JP; Lallemant B; Alfonsi M; Aubry K; Mazel M; Becher F; Perriard F; Chatelut E; Thomas F
Br J Clin Pharmacol; 2019 Jun; 85(6):1357-1366. PubMed ID: 30811063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
